Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TYRO3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TYRO3 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View TYRO3 Products |
| Gene Delivery | TYRO3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based assays. |
View TYRO3 Products |
| Benchmark Ab | Anti-TYRO3 Recombinant Biosimilar Antibody Recombinant positive control for binding and functional validation. |
View TYRO3 Products |
| Validator | TYRO3 siRNA Set Target-specific knockdown verification in vitro. |
View TYRO3 Products |
| Related Target A | AXL TAM family member; critical for counter-screening and dual-targeting selectivity assays. |
View AXL Products |
| Related Target B | MERTK TAM family member; counter-screening is vital to avoid off-target toxicity (e.g., retinal toxicity). |
View MERTK Products |
| Related Target C | GAS6 Primary ligand for TAM receptors; essential for ligand-blocking and functional inhibition assays. |
View GAS6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling within highly homologous TAM family | High-purity AXL and MERTK recombinant proteins available for rigorous counter-screening. |
| Cross-species reactivity validation (Cyno/Mouse) | Human, Mouse, and Cynomolgus TYRO3 ortholog proteins with sequence verification. |
| Lack of standardized positive controls | Sequence-verified clinical benchmark antibodies (biosimilars) included in the portfolio. |
| Assay false positives in cell-based screening | Validated siRNA knockdown sets included for target-specificity verification. |
Live TYRO3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TYRO3 therapeutics is intensifying, with major players shifting focus from traditional multi-kinase small molecules to selective monoclonal antibodies, ADCs, and multispecific immunotherapies. As first-generation pan-TAM inhibitors navigate the clinic, the next wave of R&D is targeting selective TYRO3 inhibition to bypass the toxicities associated with broader TAM blockade, particularly MERTK-driven myelosuppression and retinal issues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Preclinical programs | Solid Tumors (Melanoma, Breast, NSCLC) | Internalization Assay (Need high-purity ECD-Fc for conjugation and binding validation) |
| Bispecific Antibodies | Biotech pipelines | Immune Oncology (Cold Tumors) | Simultaneous binding kinetics (Need stable TYRO3 and co-target proteins for SPR/BLI) |
| Small Molecule Inhibitors | Incyte, Exelixis, Mirati | Refractory Solid Tumors | Selectivity Assay (Need mutant vs WT TAM family recombinant proteins for kinase profiling) |